◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Nippon Shinyaku Co., Ltd. (4516)

Name: Nippon Shinyaku Co., Ltd.（4516）— 財務諸表の推移
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

公式財務諸表に基づく売上高、利益、キャッシュフローの推移。

Healthcare · ウォール街（米国） · 最終更新: 2026-10-02

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Atthena Therapeutics, Inc.

主要指標

時価総額: JPY 228 billion
売上高（2026-03-31 期末の会計年度）: JPY 170.8B
当期純利益: JPY 29.7B
売上総利益率: 66.4%
純利益率: 17.4%

インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→

年次損益計算書

損益計算書	2026-03-31	2025-03-31	2024-03-31	2023-03-31
売上高合計	JPY 170.8B	JPY 160.2B	JPY 148.3B	JPY 144.2B
売上総利益	JPY 113.3B	JPY 109.1B	JPY 98.0B	JPY 88.2B
営業利益（EBIT）	JPY 35.5B	JPY 35.5B	JPY 33.3B	JPY 30.1B
当期純利益	JPY 29.7B	JPY 32.6B	JPY 25.9B	JPY 22.8B

出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。

貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は 4516 のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/4516

類似企業

本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。

English version →全銘柄

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.